You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

  1. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 

  2. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 

  3. CORPORATE - 19-04-2017

    Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)

    The agreement aims to improve patient access to coagulation disorders treatments in Europe

    read more 

  4. CORPORATE - 24-03-2017

    New company AO Kirov Plasma established in Russia

    It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard

    read more 
For more information please contact: pressoffice@kedrion.com